[Federal Register Volume 84, Number 220 (Thursday, November 14, 2019)]
[Notices]
[Pages 61921-61922]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24673]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of The Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Novel and 
Exceptional Technology and Research Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting. The meetings will also be videocast and can be 
accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov/).

    Name of Committee: Novel and Exceptional Technology and Research 
Advisory Committee.
    Date: December 5, 2019.
    Time: 11:00 a.m. to 5:15 p.m.
    Agenda: The Novel and Exceptional Technology and Research 
Advisory Committee (NExTRAC) will discuss (1) pathways for 
responsible innovation in emerging biotechnologies; (2) 
characteristics of emerging biotechnologies, including presentations 
on horizon scanning, gene editing in the clinic, gene drives, 
neurotechnology, artificial intelligence, and synthetic biology; and 
(3) proactively addressing scientific and societal implications of 
emerging biotechnologies. In

[[Page 61922]]

addition, charge(s) to the committee will be presented.
    Place: National Institutes of Health, Building 35A, Room 620/
630, 9000 Rockville Pike, Bethesda, MD 20892.

    Name of Committee: Novel and Exceptional Technology and Research 
Advisory Committee.
    Date: December 6, 2019.
    Time: 9:00 a.m. to 2:45 p.m.
    Agenda: The Novel and Exceptional Technology and Research 
Advisory Committee (NExTRAC) will discuss (1) pathways for 
responsible innovation in emerging biotechnologies; (2) 
characteristics of emerging biotechnologies, including presentations 
on horizon scanning, gene editing in the clinic, gene drives, 
neurotechnology, artificial intelligence, and synthetic biology; and 
(3) proactively addressing scientific and societal implications of 
emerging biotechnologies. In addition, charge(s) to the committee 
will be presented.
    Place: National Institutes of Health, Building 35A, Room 620/
630, 9000 Rockville Pike, Bethesda, MD 20892.
    Contact Person: Shayla Beckham, Management Program Analyst, 
Office of Science Policy, National Institutes of Health, 6705 
Rockledge Drive, Room 750, Bethesda, MD 20892-9606, 301-496-9838, 
[email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the NExTRAC web page: https://osp.od.nih.gov/biotechnology/novel-exceptional-technology-research-advisory-committee/, where an agenda and any additional information 
for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: November 7, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-24673 Filed 11-13-19; 8:45 am]
 BILLING CODE 4140-01-P